Abbott Laboratories $ABT Holdings Trimmed by Wedbush Securities Inc.

Wedbush Securities Inc. lowered its holdings in Abbott Laboratories (NYSE:ABT) by 9.9% in the second quarter, Holdings Channel.com reports. The firm owned 42,156 shares of the healthcare product maker’s stock after selling 4,621 shares during the period. Wedbush Securities Inc.’s holdings in Abbott Laboratories were worth $5,734,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its position in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares in the last quarter. CFO4Life Group LLC raised its holdings in shares of Abbott Laboratories by 6.4% during the first quarter. CFO4Life Group LLC now owns 2,207 shares of the healthcare product maker’s stock worth $293,000 after acquiring an additional 132 shares in the last quarter. Capital Insight Partners LLC acquired a new stake in Abbott Laboratories during the first quarter valued at $223,000. Round Rock Advisors LLC purchased a new position in Abbott Laboratories in the first quarter valued at about $201,000. Finally, Alps Advisors Inc. increased its position in Abbott Laboratories by 3.5% in the 1st quarter. Alps Advisors Inc. now owns 108,360 shares of the healthcare product maker’s stock worth $14,374,000 after purchasing an additional 3,629 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABT has been the subject of several research reports. BTIG Research reiterated a “buy” rating and set a $145.00 price target on shares of Abbott Laboratories in a report on Wednesday, October 15th. Benchmark began coverage on shares of Abbott Laboratories in a report on Friday, October 10th. They set a “buy” rating and a $145.00 price target on the stock. Raymond James Financial upped their price objective on shares of Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Evercore ISI lowered their target price on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 15th. Finally, Sanford C. Bernstein boosted their price target on Abbott Laboratories from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $147.00.

Abbott Laboratories Stock Performance

Shares of ABT opened at $126.28 on Friday. The company has a market capitalization of $219.59 billion, a PE ratio of 15.82, a price-to-earnings-growth ratio of 2.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The company’s fifty day moving average price is $130.78 and its 200 day moving average price is $131.40.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The company had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. During the same period last year, the business posted $1.21 earnings per share. The firm’s revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.